/ANVS
ANVS Stock - Annovis Bio, Inc.
Healthcare|BiotechnologyNYSE
$3.65-0.54%
$0.02 (-0.54%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+603.3%upside
Target: $25.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANVS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.61 – $3.69
TARGET (TP)$25.67
STOP LOSS$3.36
RISK/REWARD1:75.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.49
52W High$5.60
52W Low$1.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-26,694,928 | $-45,035,000 | $-25,511,279 | $-14,537,221 | $-6,640,221 |
| Net Income | $-24,590,375 | $-56,204,000 | $-25,328,567 | $-14,487,132 | $-5,462,047 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2018.50 | $-6.23 | $-3.10 | $-1.90 | $-0.87 |
Company Overview
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$31
Average Target
↑ 735.6% Upside
Now
$25
Low
$31
Average
$36
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 10th 2025 | D. Boral Capital | Downgrade | Hold | - |
| October 25th 2024 | Maxim Group | Upgrade | Buy | $25 |
| December 29th 2023 | Canaccord Genuity | Initiation | Buy | $36 |
Earnings History & Surprises
ANVSBeat Rate
56%
Last 18 quarters
Avg Surprise
-11.6%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
+19.3%
$-1.09vs$-1.35
Q2 24
+17.2%
$-0.72vs$-0.87
Q3 24
+37.1%
$-0.44vs$-0.70
Q4 24
-51.6%
$-0.97vs$-0.64
Q1 25
-13.2%
$-0.43vs$-0.38
Q2 25
+31.9%
$-0.32vs$-0.47
Q3 25
+11.1%
$-0.32vs$-0.36
Q4 25
-2.8%
$-0.37vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 20, 2026 | $-0.41 | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.36 | $-0.37 | -2.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.47 | $-0.32 | +31.9% | ✓ BEAT |
Q1 2025 | Mar 21, 2025 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.64 | $-0.97 | -51.6% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.70 | $-0.44 | +37.1% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.87 | $-0.72 | +17.2% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | $-1.35 | $-1.09 | +19.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.10 | $-1.63 | -48.2% | ✗ MISS |
Q3 2023 | Aug 15, 2023 | $-1.14 | $-1.07 | +6.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.85 | $-1.19 | -40.0% | ✗ MISS |
Q2 2023 | Apr 3, 2023 | $-1.15 | $-0.38 | +67.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-1.17 | $-0.93 | +20.5% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.64 | $-1.07 | -67.2% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.58 | $-0.72 | -24.1% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-0.25 | $-0.75 | -200.0% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.44 | $-0.35 | +20.5% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Latest News
Annovis Reveals Open-Label Extension Study For Parkinson's Disease Patients; To Begin Open-label Extension Study In January 2026; Participants Will Be Treated With Buntanetap For 36 Months
📈 PositiveBenzinga•Dec 18, 2025, 09:39 PM
Annovis Bio Announces U.S. FDA Schedules Type C Meeting In January For Company's Pathway For Parkinson's Disease Dementia
➖ NeutralBenzinga•Nov 18, 2025, 01:01 PM
Annovis Bio shares are trading higher after the company announced that data from its phase 3 trial in early Parkinson's disease showed that Buntanetap enhanced cognition in all participants.
📈 PositiveBenzinga•Nov 17, 2025, 04:24 PM
Annovis Bio Data From Phase 3 Trila In Early Parkinson's Demonstrates Buntanetap Halted Cognitive Decline Across Overall Patient Count
📈 PositiveBenzinga•Nov 17, 2025, 01:01 PM
Annovis Bio Q3 EPS $(0.37) Misses $(0.30) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 01:11 PM
Annovis Bio Says All 84 Facilities For Pivotal Phase 3 Trial In Early Alzheimer's Disease Activated, First Group Of Patients Reaches 6-Month Treatment Milestone
📈 PositiveBenzinga•Nov 6, 2025, 01:08 PM
Annovis Bio shares are trading lower after the company announced a $6 million registered direct offering of common stock.
📉 NegativeBenzinga•Oct 10, 2025, 03:10 PM
Annovis Bio Announces $6M Registered Direct Offering of Common Stock And Pre-Funded Warrants, Targeting October 13 Close For Neurodegeneration-Focused Platform
➖ NeutralBenzinga•Oct 10, 2025, 12:36 PM
ANVS stock has given up its prior gain. Annovis Bio shares were trading higher after the company announced the analysis of patient samples from the Phase 2/3 AD study.
➖ NeutralBenzinga•Oct 9, 2025, 04:55 PM
Annovis Bio shares are trading higher after the company announced the analysis of patient samples from the Phase 2/3 AD study.
📈 PositiveBenzinga•Oct 9, 2025, 01:10 PM
Annovis Bio Announces Results Showing Buntanetap's Ability To Attenuate Inflammation And Improve Cellular Health In Alzheimer's Patients, Suggesting Potential Disease-Modifying Treatment
📈 PositiveBenzinga•Oct 9, 2025, 11:34 AM
Canaccord Genuity Maintains Buy on Annovis Bio, Maintains $17 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 01:41 PM•Also:
Annovis Bio Appoints Mark Guerin As CFO
➖ NeutralBenzinga•Sep 25, 2025, 11:37 AM
Annovis Bio Highlights New Buntanetap Form In Phase 3 Alzheimer's Trial, Extends Patent Protection Into 2040s
📈 PositiveBenzinga•Sep 16, 2025, 11:38 AM
HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $10
➖ NeutralBenzinga•Sep 3, 2025, 10:56 AM
Annovis Bio Narrows Loss in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 03:10 AM
Annovis Bio GAAP EPS of -$0.32 beats by $0.06
➖ NeutralSeeking Alpha•May 13, 2025, 09:11 PM
Frequently Asked Questions about ANVS
What is ANVS's current stock price?
Annovis Bio, Inc. (ANVS) is currently trading at $3.65 per share. The stock has moved -0.54% today.
What is the analyst price target for ANVS?
The average analyst price target for ANVS is $25.67, based on 1 analyst.
What sector is Annovis Bio, Inc. in?
Annovis Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is ANVS's market cap?
Annovis Bio, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does ANVS pay dividends?
No, Annovis Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to ANVS for comparison